Wai Conrad sold $879K of CLOV (indirect holdings)

Wai Conrad (CEO, Counterpart Health) sold 220,426 indirectly-held shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $3.99 ($0.88M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wai Conrad
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and total value, plus confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling optics, but the 10b5-1 designation makes this more of a routine datapoint than a catalyst.

03

What to watch

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it is less likely to reflect new negative information about near-term prospects.

Relevance 4/10Novelty 3/10Timing: filed on 2026-05-28, after-hours/close timing for the disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp. (CLOV).

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health CEO Wai Conrad filed a Form 4 selling 220,426 shares at $3.9900 on a 10b5-1 plan, totaling about $879.5K.

Expected impact

Likely minimal immediate impact; any effect is more about sentiment than new company-specific information.

Evidence & confidence

The filing discloses an open-market sale by an officer with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification or tax planning, so the market may overreact to the headline optics.

Key entities

  • CLOVER HEALTH INVESTMENTS, CORP. /DE

    Company whose Form 4 insider sale was disclosed.

  • Wai Conrad

    CEO, Counterpart Health, reporting an indirect open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.